VBI Vaccines Inc
F:LO9A

Watchlist Manager
VBI Vaccines Inc Logo
VBI Vaccines Inc
F:LO9A
Watchlist
Price: 0.0845 EUR Market Closed
Market Cap: 2m EUR

Operating Margin
VBI Vaccines Inc

-767.1%
Current
-6 652%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-767.1%
=
Operating Profit
-72.2m
/
Revenue
9.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
VBI Vaccines Inc
NASDAQ:VBIV
808.8k USD
-767%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
407.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
28%
AU
CSL Ltd
ASX:CSL
85.1B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.2B EUR
22%
No Stocks Found

VBI Vaccines Inc
Glance View

Market Cap
2.1m EUR
Industry
Biotechnology

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.

LO9A Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-767.1%
=
Operating Profit
-72.2m
/
Revenue
9.4m
What is the Operating Margin of VBI Vaccines Inc?

Based on VBI Vaccines Inc's most recent financial statements, the company has Operating Margin of -767.1%.

Back to Top